ENDOCRINE IMAGING Flashcards

1
Q

: What is hyperparathyroidism?

A

:
A: A condition of abnormally elevated parathyroid hormone (PTH) output, which increases blood calcium and leads to hypercalcemia and bone resorption, eventually causing bone diseases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Q: What is PRIMARY hyperparathyroidism?

A

A: It is caused by hyperplasia or neoplasms in the parathyroid glands, such as adenomas or enlargement of all four glands, often due to familial syndromes like MEN I, MEN IIA, and isolated familial hyperparathyroidism. (Mutliple endocrine neoplasia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Q: What is SECONDARY hyperparathyroidism?

A

A: Increased PTH secretion in response to hypocalcemia, typically due to chronic kidney disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Q: What is the main cause of increased PTH in primary hyperparathyroidism?

A

A: Usually due to an adenoma in one of the parathyroid glands (80%) or hyperplasia of multiple glands; rarely, it is due to malignancy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Q: What are the MEN syndromes related to hyperparathyroidism?

A

A: MEN I (PPP - parathyroid, pancreatic, pituitary tumors), MEN IIA (MPP - medullary thyroid carcinoma, pheochromocytoma, parathyroid tumors), and MEN IIB (medullary thyroid carcinoma, pheochromocytoma, neuromas).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Q: What are the parathyroid-related causes of hypercalcemia?

A

A: Primary hyperparathyroidism (adenomas/MEN syndrome), lithium therapy, and familial hyperparathyroidism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Q: What other conditions can cause hypercalcemia?

A

A: Malignancies (metastatic bone disease, paraneoplastic syndrome), vitamin D intoxication, sarcoidosis, hyperthyroidism, immobilization, thiazide diuretics, vitamin A intoxication, and renal failure-related conditions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Q: What are the clinical symptoms of parathyroid hyperplasia and adenomas?
.

A

A: Many patients are asymptomatic, but symptoms can include bone cysts, decalcification, kidney stones, muscle weakness, depression, constipation, and high blood pressure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

: How is hyperparathyroidism commonly diagnosed?

A

:
A: Through routine serum calcium tests as part of biochemical testing, which often detects hypercalcemia early.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Q: What is the approach to elevated serum calcium levels?

A

A: Confirm hypercalcemia with elevated PTH levels, perform Sesta-MIBI to localize the affected gland(s), and remove the affected gland(s) with minimally invasive surgery. Repeat localization with at least two imaging modalities if disease recurs or persists (in 5% of cases).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Q: What is the principle behind the MIBI “washout” technique?

A

A: MIBI is washed out slower from pathological parathyroid glands than from normal parathyroid or thyroid glands, showing retention of activity in adenomas on late images.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Q: What is the role of Sestamibi in parathyroid imaging?

A

A: Sestamibi is used to identify pathological parathyroid glands by highlighting areas with retained radioactivity, such as adenomas.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

: What factors influence the retention of MIBI in parathyroid adenomas?
A:

Biochemical properties of the tracer: Lipophilicity and cationic charge.
Local factors: Blood flow, trans-capillary exchange, and interstitial transport.
Intracellular characteristics: Negative charge of mitochondria and membranes.

A

:
A:

Biochemical properties of the tracer: Lipophilicity and cationic charge.
Local factors: Blood flow, trans-capillary exchange, and interstitial transport.
Intracellular characteristics: Negative charge of mitochondria and membranes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Q: What does late imaging reveal in pathological parathyroid glands?

A

A: Retention of MIBI activity in adenomas, distinguishing them from normal glands.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Q: What are APUD cells?

A

A: Specialized cells that produce peptide hormones and amines from precursors, functioning as hormones or neurotransmitters.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are APUDOMAS?
.

A

A: Tumors arising from APUD cells.

17
Q

Q: Where can APUDOMAS develop?

A

A: Pituitary gland, pancreas, adrenal medulla, thyroid, gastrointestinal system, paragangliomas, and lungs.

18
Q

Q1: What type of tissue do catecholamine-secreting tumors arise from?

A

A1: Catecholamine-secreting tumors arise from sympathetic nervous tissue and the adrenal medulla.

19
Q

Q3: Name the catecholamine-secreting tumors associated with the sympathetic nervous system and adrenal medulla.

A

Benign and malignant pheochromocytomas
Adrenal medulla hyperplasia
Carcinoids
Neuroblastomas
Medullary thyroid carcinoma
Paragangliomas

20
Q

Q1: What are some radio-nuclide physiological imaging modalities used to detect catecholamine-secreting tumors?

A

→Technetium-labelled studies (e.g., bone scans with 99mTc-MDP)
→Iodine-labelled MIBG studies (e.g., 123I MIBG, 131I MIBG)
→Somatostatin receptor imaging (e.g., OctreoScan–111In, Ocreotide–123I)
FDG-PET
→ FDG-PET

21
Q

medications that block MIBG

A

check slide 35

22
Q

medication that can be used in MIBG

A

barbiturates, benzodiazepines,beta adrenergic blockers, diuretics, alpha methyldopa

23
Q

Q1: What is the difference between 123-I MIBG and 131-I MIBG in imaging catecholamine-secreting tumors?

A

123-I MIBG: Better imaging agent, used for diagnostic purposes and possibly quantification.
131-I MIBG: Used for both diagnostic imaging and as a therapeutic agent.

24
Q

Q2: What is the sensitivity of iodine-labelled MIBG studies for detecting pheochromocytomas?

A

A2: The sensitivity for detecting pheochromocytomas is 80-90%.

25
Q

Q3: What factors can affect the ability to detect pheochromocytomas using iodine-labelled MIBG studies?
A3:

A

Abnormalities in the metabolic processes like hormone uptake, storage, and secretion.
Low MIBG uptake due to insufficient storage granules in the tumor or low hormone levels.

26
Q

What percentage of pheochromocytomas will metastasize?

A

A4: Only 10% of pheochromocytomas will metastasize.

27
Q

5: What is the sensitivity for detecting carcinoid tumors using iodine-labelled MIBG studies?

A

80% if the carcinoid arises in the pancreas.
11% if it occurs in the lungs.
80% if the tumor secretes high blood levels of serotonin, regardless of its origin.

28
Q

Q6: What is the sensitivity for detecting neuroblastomas using iodine-labelled MIBG studies?

A

A6: The sensitivity for detecting neuroblastomas is 91%.

29
Q

1: What is Octreotide (Sandostatin) and what is its function in treating tumors?

A

A1: Octreotide (Sandostatin) is a somatostatin analogue that binds to receptors on tumors, reducing hormone production and release, without causing the rebound hormone increase seen with real somatostatin.

30
Q

Q2: What is the major issue with using Octreotide in certain patients?

A

A2: The major issue is that it can cause hypoglycemia in sensitive patients, such as those with insulinomas. Oral glucose should be administered prior to the study in these patients.

31
Q

Q3: What is the most commonly used radiopharmaceutical in PET imaging?

A

A3: The most commonly used radiopharmaceutical in PET imaging is 18-F FDG (di-oxy floor glucose).

32
Q

4: What are some other radiopharmaceuticals used with PET imaging?

A

Oxygen-15 (15 O) H2O
Nitrogen-13 (13 N) Ammonia
Carbon-11 (11 C) thymidine and 11 C methionine
FMISO 18 F fluoro-misonidazole
124 I labelled monoclonal antibodies
18 F Fluorinated estrogen

33
Q

Q5: What is the purpose of Octreoscan imaging?

A

n imaging involves using radioactive Octreotide to bind to somatostatin receptors in body tissues, especially tumors with high concentrations of somatostatin receptors.

34
Q

Q6: What tumors have high sensitivity for Octreoscan imaging?

A

A6:

Carcinoids: 80-100% sensitivity
Pheochromocytomas: 87% sensitivity
Neuroblastomas: 89% sensitivity
Gastrinomas: 60-90% sensitivity
Other tumors: insulinomas, pituitary tumors, paragangliomas, and medullary thyroid cancer.

35
Q
A